Allogene Therapeutics, Inc.
ALLO
$1.44
-$0.09-5.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -- |
| Cost of Revenue | -30.30% | -20.25% | -3.94% | -17.73% | -2.75% |
| Gross Profit | 30.30% | 20.25% | 3.90% | 17.69% | 2.70% |
| SG&A Expenses | -15.89% | -11.23% | -13.18% | -9.90% | -4.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.45% | -18.07% | -6.24% | -15.85% | -3.13% |
| Operating Income | 26.45% | 18.07% | 6.21% | 15.83% | 3.10% |
| Income Before Tax | 37.55% | 23.23% | 8.10% | 30.64% | -6.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.55% | 23.23% | 8.10% | 30.12% | -6.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.55% | 23.23% | 8.10% | 30.12% | -6.43% |
| EBIT | 26.45% | 18.07% | 6.21% | 15.83% | 3.10% |
| EBITDA | 27.72% | 18.26% | 5.85% | 16.28% | 2.67% |
| EPS Basic | 41.15% | 33.36% | 27.82% | 44.15% | 14.70% |
| Normalized Basic EPS | 29.82% | 31.32% | 27.81% | 32.89% | 24.89% |
| EPS Diluted | 41.15% | 33.36% | 27.82% | 44.15% | 14.70% |
| Normalized Diluted EPS | 29.82% | 31.32% | 27.81% | 32.89% | 24.89% |
| Average Basic Shares Outstanding | 6.14% | 15.21% | 27.33% | 25.09% | 24.78% |
| Average Diluted Shares Outstanding | 6.14% | 15.21% | 27.33% | 25.09% | 24.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |